The Israeli drug company Neopharm announced that it intends to market the drug "Epidiolex" in Israel, which is actually only oil CBD pure.
The drug, from the UK pharmaceutical company GW Pharmaceuticals, is the world's first cannabis-derived product and has been officially recognized as a drug by the FDA.
The drug was recently submitted by the Neophram Company to the Health Care Registry (2020). Discussions on the introduction of new drugs into the basket will be held in November 2019.
It is yet to be known whether the Ministry of Health will approve its marketing here in parallel with "ordinary" CBD oils marketed in pharmacies by medical cannabis companies or in some other manner.
In any case, "epidiolex" (Epidiolex), S.Received The first US marketing permit last year (2018) is offered for sale at a fairly high price tag 32 a thousand dollars a year. It is not yet known how much the product will cost to patients in Israel.
Epidiolex is designed to treat rare types of epilepsy that attack mainly children from the age of two - Dravet's syndrome and Lennox-Gastaut syndrome.
In clinical trials conducted in recent years on the way to FDA approval, it was found that the drug succeeded in reducing the number of epileptic seizures in 40% among patients with these diseases.
Epidiolex is the second cannabis product of GW, which is also responsible for producing "Citibox"(Sativex): Cannabis oil spray containing 50% THC and 50% CBD and marketed in Israel as well. Its high cost, up to NIS 3,000 per month, keeps those interested in getting much cheaper medical cannabis oil with exactly the same ingredients.
Neophram has resisted for years to allow the use of Cannabis Medical Blowers and has been working behind the scenes to slash the activity of companies in the industry. She also worked as an agitator to persuade doctors in oncology departments to sell the drug to patients without success.